Median plasma levels of IL6 and IL6sR were significantly higher among patients with adverse pathologic features such as lymphovascular invasion, lymph node metastasis and advanced pathologic tumor stage (p-values < 0.05, Table 1). Here, IL6 is linked to metastatic malignant neoplasm in the lymph nodes.